RECRUITING

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Description

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Study Overview

Study Details

Study overview

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Bemnifosbuvir and Ruzasvir Administered as a Fixed-Dose Combination in Adult Participants With Severe Renal or Hepatic Impairment in Comparison to Healthy Participants

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Condition
Healthy Volunteer Study
Intervention / Treatment

-

Contacts and Locations

Orlando

Atea Study Site, Orlando, Florida, United States, 32809

Tampa

Atea Study Site, Tampa, Florida, United States, 33603

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
  • * Females must have a negative pregnancy test at Screening and prior to dosing
  • * BMI of 18.5 to 43.0 kg/m2
  • * Willing to comply with the study requirements and to provide written informed consent
  • * Considered stable in the judgement of an Investigator
  • * Presence of severe renal impairment or kidney failure (as defined by eGFR\< 30 mL/ min)
  • * Considered stable for at least 1 month prior to Screening, as per the judgement of an Investigator
  • * Presence of severe hepatic impairment (Child-Pugh Class C: score of 10 to 15).
  • * Medically healthy, in the opinion of an Investigator
  • * Must match by gender, age (± 10 years), and BMI (within 20%) to the pooled mean values of subjects with severe renal and hepatic impairment
  • * Pregnant or breastfeeding
  • * Infected with hepatitis B virus, hepatitis C virus or HIV
  • * Abuse of alcohol or drugs
  • * Use of other investigational drugs within 28 days of dosing
  • * Other clinically significant medical conditions or laboratory abnormalities
  • * Presence of poorly controlled Type 1 or Type 2 diabetes as defined by Hemoglobin A1c \> 10%
  • * Undergoing any method of dialysis
  • * Subjects requiring treatment for hepatic impairment or other chronic disease must be on a stable treatment plan
  • * History of renal transplant
  • * Concurrent use of medications known to affect the elimination of serum creatinine
  • * History of liver transplant
  • * Evidence of hepatic carcinoma presence at Screening

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Atea Pharmaceuticals, Inc.,

Study Record Dates

2025-08